MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fendo.2024.1418936

Медицинская библиотека · Frontiers in endocrinology · 2024

The effect of Chinese herbal medicine on male factor infertility: study protocol for a randomized controlled trial.

Wen Qidan, Xu Huanying, Zou Haoxi, Wang Pei, Xing Xiaoyan, Chen Ying, Zhu Qiaoling, Chen Yu, Tan Minhua, Zhang Miaomiao, Pan Ting, Chen Yanfen, Wang Yingju, Wu Suzhen

Протокол клинического исследованияСтатьяПеревод в очереди

Аннотация

BACKGROUND

The global prevalence of infertility is 9%, with male factors potentially accounting for 40% to 60% of cases. Conventional treatments can be ineffective, invasive, costly, and linked to adverse effects and high risks. Previous studies have shown that, Chinese herbal medicine (CHM) can regulate the hypothalamus-pituitary-testis axis, improve sperm abnormalities and quality, mitigate oxidative stress, and decrease DNA fragmentation index (DFI). Yet, the evidence backing the use of Chinese herbal medicine (CHM) for treating male factor infertility lacks conviction due to study design limitations, and there remains a scarcity of studies on the live birth rate following CHM treatment for male factor infertility. Here, we describe the rationale and design of a randomized waitlist-controlled trial to evaluate the effect of CHM on the live birth rate among males with infertility.

METHODS

This study is a single-center, randomized, waitlist-controlled study. A total of 250 couples diagnosed with male factor infertility will be enrolled in this study and then randomly allocated into two groups in a 1:1 ratio. Male participants in CHM group (treatment group) will receive CHM once a day for 3 months. Male participants in the waitlist group (control group) will not receive any treatment for 3 months. After 3 months, participants in both groups need to be followed up for another 12 months. The primary outcome will be the live birth rate; secondary outcomes include semen quality parameters, DFI and pregnancy related outcomes. Safety will also be assessed.

DISCUSSION: The purpose of this trial is to explore the effects and safety of CHM on the live birth rate among couples dealing with male factor infertility. The outcome of this trial may provide a viable treatment option for male factor infertility.

TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR2200064416. Registered on 7 October 2022, https://www.chictr.org.cn.

Для цитирования: Wen Qidan, Xu Huanying, Zou Haoxi, Wang Pei, Xing Xiaoyan, Chen Ying, Zhu Qiaoling, Chen Yu, Tan Minhua, Zhang Miaomiao, Pan Ting, Chen Yanfen, Wang Yingju, Wu Suzhen. The effect of Chinese herbal medicine on male factor infertility: study protocol for a randomized controlled trial.. Frontiers in endocrinology. 2024. DOI: 10.3389/fendo.2024.1418936.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.